rasagiline Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
monoamine oxydase (MAO)-inhibitors type B	3521	136236-51-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: TVP-1022 rasagiline hydrochloride rasagiline azilect (R)-(+)-Rasagiline rasagiline mesylate TV-1030 rasagiline mesilate	Rasagiline is a selective, irreversible MAO-B inhibitor indicated for the treatment of idiopathic Parkinson's disease. The results of a clinical trial designed to examine the effects of rasagiline tablets on blood pressure when it is administered with increasing doses of tyramine indicates the functional selectivity can be incomplete when healthy subjects ingest large amounts of tyramine while receiving recommended doses of rasagiline tablets. The selectivity for inhibiting MAO-B diminishes in a dose-related manner. One mechanism is believed to be related to its MAO-B inhibitory activity, which causes an increase in extracellular levels of dopamine in the striatum. The elevated dopamine level and subsequent increased dopaminergic activity are likely to mediate rasagiline’s beneficial effects seen in models of dopaminergic motor dysfunction. Molecular weight: 171.24 Formula: C12H13N CLOGP: 2.34 LIPINSKI: 0 HAC: 1 HDO: 1 TPSA: 12.03 ALOGS: -3.84 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

TVP-1022
rasagiline hydrochloride
rasagiline
azilect
(R)-(+)-Rasagiline
rasagiline mesylate
TV-1030
rasagiline mesilate

Rasagiline is a selective, irreversible MAO-B inhibitor indicated for the treatment of idiopathic Parkinson's disease. The results of a clinical trial designed to examine the effects of rasagiline tablets on blood pressure when it is administered with increasing doses of tyramine indicates the functional selectivity can be incomplete when healthy subjects ingest large amounts of tyramine while receiving recommended doses of rasagiline tablets. The selectivity for inhibiting MAO-B diminishes in a dose-related manner. One mechanism is believed to be related to its MAO-B inhibitory activity, which causes an increase in extracellular levels of dopamine in the striatum. The elevated dopamine level and subsequent increased dopaminergic activity are likely to mediate rasagiline’s beneficial effects seen in models of dopaminergic motor dysfunction.

Molecular weight: 171.24
Formula: C12H13N
CLOGP: 2.34
LIPINSKI: 0
HAC: 1
HDO: 1
TPSA: 12.03
ALOGS: -3.84
ROTB: 2

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
1	mg	O

ADMET properties:

Property	Value	Reference
BA (Bioavailability)	36 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
May 16, 2006	FDA	TEVA
March 23, 2018	PMDA	Takeda Pharmaceutical Company Limited

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Dyskinesia	109.86	43.31	26	489	4763	2352807
Confusional state	98.29	43.31	34	481	24310	2333260
Serotonin syndrome	90.48	43.31	21	494	3519	2354051
Hallucination, visual	88.62	43.31	20	495	2959	2354611
Drug interaction	77.65	43.31	30	485	29133	2328437
Fall	60.69	43.31	29	486	47070	2310500
Compulsive shopping	58.39	43.31	9	506	160	2357410
Hallucination	55.57	43.31	17	498	8131	2349439
Gambling disorder	54.72	43.31	9	506	245	2357325
Parkinson's disease	50.96	43.31	11	504	1315	2356255
Pleurothotonus	47.32	43.31	8	507	258	2357312
Hypertension	44.97	43.31	20	495	27341	2330229
Hypersexuality	44.61	43.31	7	508	140	2357430
Coronary artery dissection	43.89	43.31	7	508	156	2357414

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Impulse-control disorder	152.11	44.12	25	635	310	1745811
Dyskinesia	140.03	44.12	35	625	3784	1742337
Orthostatic hypotension	128.51	44.12	32	628	3399	1742722
Hypersexuality	122.19	44.12	21	639	345	1745776
Hallucination	113.68	44.12	35	625	8135	1737986
Gambling disorder	99.88	44.12	18	642	392	1745729
Serotonin syndrome	89.40	44.12	23	637	2765	1743356
On and off phenomenon	86.45	44.12	15	645	260	1745861
Parkinson's disease	84.27	44.12	20	640	1722	1744399
Fall	72.71	44.12	35	625	27179	1718942
Confusional state	71.20	44.12	32	628	21246	1724875
Condition aggravated	68.19	44.12	31	629	21119	1725002
Oesophageal achalasia	67.66	44.12	10	650	57	1746064
Delirium	66.60	44.12	22	638	6340	1739781
Hallucination, visual	62.14	44.12	17	643	2575	1743546
Muscle rigidity	57.97	44.12	15	645	1833	1744288
Compulsive shopping	56.16	44.12	9	651	93	1746028
Dopamine dysregulation syndrome	54.40	44.12	9	651	115	1746006
Stereotypy	54.40	44.12	9	651	115	1746006
Loss of consciousness	51.64	44.12	23	637	14852	1731269
Dizziness	51.27	44.12	30	630	34331	1711790
Abnormal behaviour	50.95	44.12	18	642	6324	1739797
Drug interaction	48.63	44.12	27	633	27931	1718190
Paraphilia	48.46	44.12	7	653	33	1746088
Thunderclap headache	48.35	44.12	6	654	5	1746116
Psychotic disorder	46.97	44.12	16	644	5040	1741081
Akinesia	46.31	44.12	9	651	296	1745825
Neuroleptic malignant syndrome	45.76	44.12	14	646	3134	1742987

Pharmacologic Action:

Source	Code	Description
ATC	N04BD02	NERVOUS SYSTEM ANTI-PARKINSON DRUGS DOPAMINERGIC AGENTS Monoamine oxidase B inhibitors
FDA EPC	N0000175744	Monoamine Oxidase Inhibitor
CHEBI has role	CHEBI:63726	neuroprotective agent
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D008996	Monoamine Oxidase Inhibitors
MeSH PA	D018696	Neuroprotective Agents
MeSH PA	D020011	Protective Agents

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Parkinson's disease	indication	49049000	DOID:14330
Dyskinesia	contraindication	9748009
Bipolar disorder	contraindication	13746004	DOID:3312
Orthostatic hypotension	contraindication	28651003
Hypertensive disorder	contraindication	38341003	DOID:10763
Epilepsy	contraindication	84757009	DOID:1826
Disease of liver	contraindication	235856003	DOID:409
Pheochromocytoma	contraindication	302835009
Malignant melanoma	contraindication	372244006

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.54	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 0.5MG BASE	AZILECT	TEVA	N021641	May 16, 2006	RX	TABLET	ORAL	7815942	Aug. 27, 2027	TREATMENT OF PARKINSON'S DISEASE
EQ 1MG BASE	AZILECT	TEVA	N021641	May 16, 2006	RX	TABLET	ORAL	7815942	Aug. 27, 2027	TREATMENT OF PARKINSON'S DISEASE

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Amine oxidase [flavin-containing] B	Enzyme	P27338	AOFB_HUMAN	INHIBITOR	Ki	6.15	CHEMBL	CHEMBL
Amine oxidase [flavin-containing] A	Enzyme	P21397	AOFA_HUMAN		Ki	5.01	CHEMBL
Amine oxidase [flavin-containing] A	Enzyme		AOFA_RAT		IC50	6.39	CHEMBL
Amine oxidase [flavin-containing] B	Enzyme		AOFB_RAT		IC50	8.36	CHEMBL

External reference:

ID	Source
4025261	VUID
N0000179514	NUI
C0525678	UMLSCUI
D02562	KEGG_DRUG
003N66TS6T	UNII
7151	INN_ID
136236-50-5	SECONDARY_CAS_RN
419010007	SNOMEDCT_US
418734001	SNOMEDCT_US
134748	RXNORM
d05612	MMSL
4025261	VANDF
010775	NDDF
162358	MMSL
3052776	PUBCHEM_CID
CHEBI:63620	CHEBI
CHEMBL887	ChEMBL_ID
RAS	PDB_CHEM_ID
RAU	PDB_CHEM_ID
DB01367	DRUGBANK_ID
CHEMBL1201142	ChEMBL_ID
CHEMBL1235738	ChEMBL_ID
C031967	MESH_SUPPLEMENTAL_RECORD_UI
6641	IUPHAR_LIGAND_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Rasagiline	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3060	TABLET	0.50 mg	ORAL	NDA AUTHORIZED GENERIC	17 sections
Rasagiline	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3061	TABLET	1 mg	ORAL	NDA AUTHORIZED GENERIC	17 sections
Rasagiline Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-1270	TABLET	0.50 mg	ORAL	ANDA	17 sections
Rasagiline Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-1271	TABLET	1 mg	ORAL	ANDA	17 sections
Rasagiline	HUMAN PRESCRIPTION DRUG LABEL	1	16714-770	TABLET	0.50 mg	ORAL	ANDA	17 sections
Rasagiline	HUMAN PRESCRIPTION DRUG LABEL	1	16714-771	TABLET	1 mg	ORAL	ANDA	17 sections
Rasagiline Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	23155-746	TABLET	0.50 mg	ORAL	ANDA	16 sections
Rasagiline Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	23155-747	TABLET	1 mg	ORAL	ANDA	16 sections
RASAGILINE	HUMAN PRESCRIPTION DRUG LABEL	1	42571-220	TABLET	0.50 mg	ORAL	ANDA	17 sections
RASAGILINE	HUMAN PRESCRIPTION DRUG LABEL	1	42571-221	TABLET	1 mg	ORAL	ANDA	17 sections
Azilect	HUMAN PRESCRIPTION DRUG LABEL	1	43353-015	TABLET	1 mg	ORAL	NDA	19 sections
Rasagiline Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	47781-138	TABLET	0.50 mg	ORAL	ANDA	17 sections
Rasagiline Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	47781-139	TABLET	1 mg	ORAL	ANDA	17 sections
Rasagiline	HUMAN PRESCRIPTION DRUG LABEL	1	47781-683	TABLET	0.50 mg	ORAL	ANDA	17 sections
Rasagiline	HUMAN PRESCRIPTION DRUG LABEL	1	47781-690	TABLET	1 mg	ORAL	ANDA	17 sections
Azilect	HUMAN PRESCRIPTION DRUG LABEL	1	54868-6206	TABLET	1 mg	ORAL	NDA	18 sections
Rasagiline	HUMAN PRESCRIPTION DRUG LABEL	1	67877-259	TABLET	0.50 mg	ORAL	ANDA	17 sections
Rasagiline	HUMAN PRESCRIPTION DRUG LABEL	1	67877-260	TABLET	1 mg	ORAL	ANDA	17 sections
Azilect	HUMAN PRESCRIPTION DRUG LABEL	1	68546-142	TABLET	0.50 mg	ORAL	NDA	17 sections
Azilect	HUMAN PRESCRIPTION DRUG LABEL	1	68546-229	TABLET	1 mg	ORAL	NDA	17 sections